AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35060759 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NMT) intervention, 8 weeks duration, 2 times per week, guided strength exercises with landing stabilization focus.
Number of subjects: 27
Study 35060759 — intervention group
Group type: COMPARATOR
Intervention: Standard of care, no recommendations provided.
Number of subjects: 27
Study 35060759 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 27
Study 35060759 — intervention group
Group type: EXPERIMENTAL
Intervention: NMT intervention
Number of subjects: 27
Study 35060759 — intervention group
Group type: EXPERIMENTAL
Intervention: NMT intervention and standard of care
Number of subjects: 27
Study 34329963 — intervention group
Group type: EXPERIMENTAL
Intervention: Double scenario simulations
Number of subjects: 146
Study 34329963 — intervention group
Group type: COMPARATOR
Intervention: Single scenario simulations
Number of subjects: 146
Study 32122284 — intervention group
Group type: EXPERIMENTAL
Intervention: Racial exclusion (vs. inclusion)
Number of subjects: 276
Study 35834198 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Reality smoking cues (extinction condition)
Number of subjects: 129
Study 35834198 — intervention group
Group type: COMPARATOR
Intervention: Augmented Reality neutral cues (control condition)
Number of subjects: 129
Study 33470595 — intervention group
Group type: COMPARATOR
Intervention: Hemiarthroplasty (HA)
Number of subjects: 31
Study 33470595 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse shoulder arthroplasty (RSA)
Number of subjects: 31
Study 33470595 — intervention group
Group type: COMPARATOR
Intervention: Visual analog scale for pain, DASH scores, SF‐12 scores, radiographic outcomes
Number of subjects: 31
Study 34363558 — intervention group
Group type: EXPERIMENTAL
Intervention: gilteritinib (120 mg/day)
Number of subjects: 48
Study 34363558 — intervention group
Group type: COMPARATOR
Intervention: salvage chemotherapy (SC)
Number of subjects: 48
Study 35410211 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based learning (TBL) in bedside teaching
Number of subjects: 30
Study 35410211 — intervention group
Group type: COMPARATOR
Intervention: Traditional bedside teaching
Number of subjects: 30
Study 32164886 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg daily or maximum tolerated dose up to 1.8 mg daily)
Number of subjects: 9340
Study 32164886 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard care
Number of subjects: 9340
Study 34143186 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (Amoxicillin & Clavulanic Acid)
Number of subjects: 0
Study 34143186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32696304 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone calls and assistance scheduling mammograms
Number of subjects: 890
Study 32696304 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 890
Study 35297744 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLSTER intervention (10-week duration)
Number of subjects: 15
Study 35297744 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLSTER intervention (4-week duration)
Number of subjects: 15
Study 33215895 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Trigger Tool (GTT)
Number of subjects: 120
Study 33771205 — intervention group
Group type: EXPERIMENTAL
Intervention: GV1001 1.12 mg
Number of subjects: 96
Study 33771205 — intervention group
Group type: EXPERIMENTAL
Intervention: GV1001 0.56 mg
Number of subjects: 96
Study 33771205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 35063242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornelian cherry fruit extract (20 cc/d for 12 weeks)
Number of subjects: 50
Study 35063242 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 cc/d for 12 weeks)
Number of subjects: 50
Study 33109935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention participants received an individualized linkage plan and minibooster sessions.
Number of subjects: 146
Study 33109935 — intervention group
Group type: COMPARATOR
Intervention: Control participants received treatment as usual.
Number of subjects: 146
Study 33109935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention participants were linked to PrEP care significantly sooner than control participants.
Number of subjects: 146
Study 32622610 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum feeding (CF)
Number of subjects: 24
Study 32622610 — intervention group
Group type: COMPARATOR
Intervention: Mixture of 50% colostrum and 50% whole milk
Number of subjects: 24
Study 32622610 — intervention group
Group type: COMPARATOR
Intervention: Whole milk
Number of subjects: 24
Study 36266930 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Performance Coaching (OPC) - eight weekly sessions
Number of subjects: 44
Study 36266930 — intervention group
Group type: COMPARATOR
Intervention: Usual self-care education
Number of subjects: 44
Study 34848584 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC+DTG
Number of subjects: 0
Study 34848584 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF/FTC+DTG
Number of subjects: 0
Study 34848584 — intervention group
Group type: COMPARATOR
Intervention: TDF/FTC/EFV
Number of subjects: 0
Study 35606886 — intervention group
Group type: EXPERIMENTAL
Intervention: TF‐CBTp + treatment as usual (TAU)
Number of subjects: 300
Study 35606886 — intervention group
Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 300
Study 33788296 — intervention group
Group type: EXPERIMENTAL
Intervention: MD+LPS (5 mg/kg)
Number of subjects: 4
Study 33788296 — intervention group
Group type: COMPARATOR
Intervention: Control+LPS (5 mg/kg)
Number of subjects: 4
Study 32134851 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg
Number of subjects: 0
Study 32134851 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 25 mg
Number of subjects: 0
Study 32134851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35606010 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir, a novel antiviral medicine aimed at reducing the ability of SARS-CoV-2 to multiply in the body.
Number of subjects: 0
Study 35606010 — intervention group
Group type: COMPARATOR
Intervention: Standard of care for COVID-19 patients as provided by the National Health Service in England.
Number of subjects: 0
Study 35842120 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydronidone 180 mg/day
Number of subjects: 168
Study 35842120 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydronidone 270 mg/day
Number of subjects: 168
Study 35842120 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydronidone 360 mg/day
Number of subjects: 168
Study 35842120 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hydronidone group
Number of subjects: 168
Study 35842120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 32949315 — intervention group
Group type: EXPERIMENTAL
Intervention: NPDC program model
Number of subjects: 486
Study 32949315 — intervention group
Group type: COMPARATOR
Intervention: SAU (services as usual)
Number of subjects: 486
Study 32723349 — intervention group
Group type: EXPERIMENTAL
Intervention: AWARE risk reduction program
Number of subjects: 200
Study 32723349 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200
Study 36089558 — intervention group
Group type: EXPERIMENTAL
Intervention: Buzzy
Number of subjects: 161
Study 36089558 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold spray
Number of subjects: 161
Study 36089558 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 161
Study 36089558 — intervention group
Group type: EXPERIMENTAL
Intervention: Buzzy and cold spray
Number of subjects: 161
Study 33230607 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo group (n = 30)
Number of subjects: 60
Study 33230607 — intervention group
Group type: COMPARATOR
Intervention: Non-photo group (n = 30)
Number of subjects: 60
Study 33230607 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 36113906 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (ImRs), 16 sessions; n = 21
Number of subjects: 61
Study 36113906 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills training in Affective and Interpersonal Regulation (STAIR) followed by ImRs, 8 STAIR sessions followed by 16 ImRs sessions; n = 20
Number of subjects: 61
Study 36113906 — intervention group
Group type: COMPARATOR
Intervention: Waitlist, 8 weeks; n = 20
Number of subjects: 61
Study 36113906 — intervention group
Group type: EXPERIMENTAL
Intervention: ImRs (after waitlist completion), total n for this condition = 30
Number of subjects: 61
Study 36113906 — intervention group
Group type: EXPERIMENTAL
Intervention: STAIR/ImRs (after waitlist completion), total n for this condition = 31
Number of subjects: 61
Study 32598568 — intervention group
Group type: EXPERIMENTAL
Intervention: DHAV-1 infection in non-embryonated eggs
Number of subjects: 90
Study 32598568 — intervention group
Group type: EXPERIMENTAL
Intervention: DHAV-1 infection in 17-day-old embryos
Number of subjects: 90
Study 32598568 — intervention group
Group type: EXPERIMENTAL
Intervention: DHAV-1 infection in dead embryos
Number of subjects: 90
Study 32598568 — intervention group
Group type: EXPERIMENTAL
Intervention: DHAV-1 infection in newly hatched ducklings
Number of subjects: 90
Study 32598568 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall detection of DHAV-1
Number of subjects: 90
Study 32598568 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenicity of DHAV-1 isolates
Number of subjects: 90
Study 35312941 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Number of subjects: 45
Study 35312941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 35308141 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurology nursing (SG)
Number of subjects: 110
Study 35308141 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing (CG)
Number of subjects: 110
Study 34726849 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine powder air polishing
Number of subjects: 85
Study 34726849 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine powder air polishing followed by application of sponge floss
Number of subjects: 85
Study 34726849 — intervention group
Group type: COMPARATOR
Intervention: Control treatments (sponge floss only, ultrasonic device with polyetheretherketone fibre tip coating, and manual scaling with carbon fibre curettes and use of sponge floss)
Number of subjects: 85
Study 35337306 — intervention group
Group type: EXPERIMENTAL
Intervention: All-inside ACLR
Number of subjects: 54
Study 35337306 — intervention group
Group type: COMPARATOR
Intervention: Standard ACLR
Number of subjects: 54
Study 33467641 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT and nutrition intervention (school-based program)
Number of subjects: 48
Study 34130550 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 fish oil (3200 mg/day)
Number of subjects: 30
Study 34130550 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 30
Study 32889959 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioenhanced curcumin (BEC) 50 mg twice daily
Number of subjects: 69
Study 32889959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 36196673 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological resilience
Number of subjects: 3199
Study 34355337 — intervention group
Group type: EXPERIMENTAL
Intervention: Antral resection sleeve gastrectomy (Group A)
Number of subjects: 36
Study 34355337 — intervention group
Group type: COMPARATOR
Intervention: Antral preservation sleeve gastrectomy (Group B)
Number of subjects: 36
Study 32575441 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate extract 20 mL (720 mg phenolic compounds) for two weeks
Number of subjects: 18
Study 32575441 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 18
Study 32575441 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 18
Study 35729622 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interview counseling
Number of subjects: 448
Study 35729622 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging grounded in behavioral economics
Number of subjects: 448
Study 35729622 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education
Number of subjects: 448
Study 35729622 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to testing (via navigation to an appointment vs. a self-test kit)
Number of subjects: 448
Study 34154490 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal Binder (AB)
Number of subjects: 346
Study 32349413 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-based training program (30 min/day, 2 days/week for 3 months)
Number of subjects: 21
Study 32349413 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 35761219 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma plus standard therapy (CP + ST)
Number of subjects: 101
Study 35761219 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone (ST)
Number of subjects: 101
Study 33394545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILS) including achieving ≥7% weight loss, ≥150 min/wk of moderate leisure-time physical activity, and/or a goal for self-reported total fat intake.
Number of subjects: 823
Study 33394545 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of the weight loss goal.
Number of subjects: 823
Study 33394545 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of the physical activity goal.
Number of subjects: 823
Study 33394545 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of the diet goal.
Number of subjects: 823
Study 32183736 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC
Number of subjects: 326
Study 32183736 — intervention group
Group type: COMPARATOR
Intervention: Standard R0 D2 followed by 8 cycles of adjuvant chemotherapy (AC) with oxaliplatin and S-1 (SOX) regimen
Number of subjects: 326
Study 34327732 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (2400 mg over 5 days)
Number of subjects: 40
Study 34327732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 33347002 — intervention group
Group type: EXPERIMENTAL
Intervention: Prabotulinum toxin A (24 units)
Number of subjects: 90
Study 33347002 — intervention group
Group type: EXPERIMENTAL
Intervention: Prabotulinum toxin A (48 units)
Number of subjects: 90
Study 33347002 — intervention group
Group type: EXPERIMENTAL
Intervention: Prabotulinum toxin A (72 units)
Number of subjects: 90
Study 33347002 — intervention group
Group type: EXPERIMENTAL
Intervention: Prabotulinum toxin A (96 units)
Number of subjects: 90
Study 33347002 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 90
Study 34787823 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.5 mg
Number of subjects: 58
Study 34787823 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 58
Study 34787823 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 58
Study 34787823 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly dulaglutide doses for 4 weeks
Number of subjects: 58
Study 34787823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 34091608 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics plus bronchoscopic suction every other day
Number of subjects: 0
Study 34091608 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics with daily closed-suction
Number of subjects: 0
Study 32998911 — intervention group
Group type: EXPERIMENTAL
Intervention: Audible signs of respiratory dysfunction (inspiratory stridor, expiratory wheeze, combined stridor+wheeze, cough)
Number of subjects: 48
Study 32998911 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up clinical workup for EIA
Number of subjects: 48
Study 33514329 — intervention group
Group type: EXPERIMENTAL
Intervention: VIVIFRAIL© multicomponent exercise program performed five times a week (2 times supervised, 3 times home-based) for 12 weeks
Number of subjects: 44
Study 33514329 — intervention group
Group type: EXPERIMENTAL
Intervention: VIVIFRAIL© multicomponent exercise program
Number of subjects: 44
Study 33514329 — intervention group
Group type: COMPARATOR
Intervention: Health education meetings
Number of subjects: 44
Study 33146438 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) cycling, goal‐directed training, and adapted cycling
Number of subjects: 21
Study 33146438 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 21
Study 32660791 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fried food consumption
Number of subjects: 2043
Study 32660791 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing 100 g/day of fried food with non-fried food
Number of subjects: 2043
Study 32660791 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing 100 g/day of fried protein-rich food
Number of subjects: 2043
Study 32660791 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing 100 g/day of fried eggs
Number of subjects: 2043
Study 32660791 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing 100 g/day of fried fish
Number of subjects: 2043
Study 32660791 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased olive oil intake
Number of subjects: 2043
Study 32660791 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil with non-fried food
Number of subjects: 2043
Study 32992642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Epidural Bolus (IEB)
Number of subjects: 938
Study 32992642 — intervention group
Group type: COMPARATOR
Intervention: Continuous Epidural Infusion (CEI)
Number of subjects: 938
Study 35488883 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-visit root canal retreatment
Number of subjects: 100
Study 35488883 — intervention group
Group type: COMPARATOR
Intervention: Two-visit root canal retreatment (control)
Number of subjects: 100
Study 34343658 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab (Dara) with or without standard chemotherapy
Number of subjects: 0
Study 34343658 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (as a control)
Number of subjects: 0
Study 32018062 — intervention group
Group type: EXPERIMENTAL
Intervention: Remestemcel-L therapy (2 × 10^6 cells/kg twice weekly for 4 weeks)
Number of subjects: 54
Study 32018062 — intervention group
Group type: EXPERIMENTAL
Intervention: Remestemcel-L therapy
Number of subjects: 54
Study 33840074 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsivity (measured by I-8 subscales)
Number of subjects: 519
Study 33840074 — intervention group
Group type: EXPERIMENTAL
Intervention: Maladaptive personality traits (measured by PID-5 subscales)
Number of subjects: 519
Study 33840074 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactions between personality traits and impulsivity
Number of subjects: 519
Study 34142740 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) preconditioning for 30 minutes
Number of subjects: 8
Study 34142740 — intervention group
Group type: COMPARATOR
Intervention: Control group (40-min seated-rest)
Number of subjects: 8
Study 34142740 — intervention group
Group type: COMPARATOR
Intervention: Exercise (30-min seated-rest followed by 150 knee-squats)
Number of subjects: 8
Study 36103288 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermolina-Henna cream
Number of subjects: 0
Study 36103288 — intervention group
Group type: COMPARATOR
Intervention: Mometasone cream
Number of subjects: 0
Study 36235569 — intervention group
Group type: EXPERIMENTAL
Intervention: BSG extract-based food supplement
Number of subjects: 40
Study 36235569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 34160184 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Behavioral Nutrition (PBN)
Number of subjects: 60
Study 34160184 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 32158971 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous antibiotic prophylaxis (CAP) until hydronephrosis resolution or aged 12 months (n=40)
Number of subjects: 80
Study 32158971 — intervention group
Group type: COMPARATOR
Intervention: Watchful observation (control group, n=40)
Number of subjects: 80
Study 32158971 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous antibiotic prophylaxis (CAP)
Number of subjects: 80
Study 35512620 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-based computer AT system (CATS)
Number of subjects: 65
Study 35512620 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 65
Study 35512620 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual P300 component
Number of subjects: 65
Study 33962686 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on the Social Marketing Model
Number of subjects: 94
Study 32802833 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA)
Number of subjects: 63
Study 32802833 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) combined with oral finasteride (FNS)
Number of subjects: 63
Study 32607820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent 'Internet Plus'-based full disease cycle remote ischemic conditioning (i-RIC)
Number of subjects: 4700
Study 32607820 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving PCI and usual care
Number of subjects: 4700
Study 32059663 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally tailored preconception care (PCC) approach
Number of subjects: 2000
Study 35293588 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral task-oriented training with dynamic hand orthosis (30 min per day)
Number of subjects: 30
Study 35293588 — intervention group
Group type: COMPARATOR
Intervention: Unilateral task-oriented training without dynamic hand orthosis
Number of subjects: 30
Study 32860964 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 778